Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
There are several ways of personalizing PRRT (peptide receptor radionuclide treatment) in NEN
(neuroendocrine neoplasia). Nevertheless, the current treatment regimen is not personalized.
This trial aims to compare personalized PRRT to non-personalized PRRT in terms of safety,
efficacy and resource demands in order to optimize treatment outcomes in an evidence-based
manner in future.